ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 155 filers reported holding ASCENDIS PHARMA A/S in Q3 2020. The put-call ratio across all filers is 0.38 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $314,162 | -0.3% | 3,355 | -5.0% | 0.00% | – |
| Q2 2023 | $315,231 | -17.9% | 3,532 | -1.4% | 0.00% | – |
| Q1 2023 | $383,955 | -9.2% | 3,581 | +3.5% | 0.00% | – |
| Q4 2022 | $422,692 | -8.7% | 3,461 | -22.7% | 0.00% | – |
| Q3 2022 | $463,000 | +5.7% | 4,480 | -5.0% | 0.00% | – |
| Q2 2022 | $438,000 | -24.4% | 4,716 | -4.4% | 0.00% | – |
| Q1 2022 | $579,000 | -85.6% | 4,934 | -83.5% | 0.00% | -100.0% |
| Q4 2021 | $4,028,000 | -11.5% | 29,942 | +4.9% | 0.00% | -25.0% |
| Q3 2021 | $4,550,000 | +33.1% | 28,544 | +9.8% | 0.00% | +33.3% |
| Q2 2021 | $3,419,000 | +10.1% | 25,987 | +7.8% | 0.00% | 0.0% |
| Q1 2021 | $3,106,000 | -12.0% | 24,103 | +13.9% | 0.00% | -25.0% |
| Q4 2020 | $3,529,000 | +10.9% | 21,161 | +2.6% | 0.00% | 0.0% |
| Q3 2020 | $3,183,000 | +1272.0% | 20,629 | +1212.3% | 0.00% | – |
| Q2 2020 | $232,000 | +6.4% | 1,572 | +0.3% | 0.00% | – |
| Q4 2019 | $218,000 | -36.1% | 1,567 | -45.9% | 0.00% | -100.0% |
| Q1 2019 | $341,000 | – | 2,895 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
| Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
| Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
| Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
| Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
| Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
| Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
| Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
| Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
| Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |